PMID- 15274387
OWN - NLM
STAT- MEDLINE
DCOM- 20040909
LR  - 20161019
IS  - 0250-7005 (Print)
IS  - 0250-7005 (Linking)
VI  - 24
IP  - 3b
DP  - 2004 May-Jun
TI  - Correlation of serum VEGF levels with clinical stage, therapy efficacy, tumor 
      metastasis and patient survival in ovarian cancer.
PG  - 1973-9
AB  - Vascular endothelial growth factor (VEGF) has been shown to play an important 
      role in tumor growth and progression. However, the clinical implications of VEGF 
      expression in ovarian tumors are not fully understood. We therefore investigated 
      the serum level of VEGF in patients with ovarian tumors and explored the 
      potential use of VEGF as a tumor marker for diagnosis, treatment and prognosis of 
      human ovarian cancer. The serum VEGF (sVEGF) levels in 120 patients with ovarian 
      carcinoma, 25 patients with benign ovarian tumor and 90 healthy female blood 
      donors were measured by an enzyme-linked immunosorbent assay in this study. We 
      also determined the levels of sVEGF in patients with epithelial ovarian cancer 
      before and after surgery. Our results showed that: (i) ovarian cancer patients 
      had significantly higher levels of sVEGF compared to those of patients with 
      benign ovarian tumor or those of healthy individuals. As a cut-off at 100 pg/ml, 
      the sensitivity and specificity of sVEGF levels for diagnosing ovarian carcinoma 
      were 77.1% and 87%, respectively. (ii) sVEGF levels were markedly elevated in 
      patients with advanced stage or poorly-differentiated ovarian cancer, as well as 
      in those with more ascites (>500 ml), as compared to patients with early stage 
      and well-differentiated ovarian cancer, or those with less ascites (<500 ml). 
      However, there was no significant difference in sVEGF levels among different 
      pathological subtypes of ovarian carcinoma. (iii) The post-operative sVEGF levels 
      were significantly lower than the pre-operative sVEGF levels. (iv) We measured 
      significantly higher levels of sVEGF in patients with metastasis as compared to 
      patients lacking metastasis. Lastly (v) the average survival-time in patients 
      with higher levels of sVEGF (>100 pg/ml) was 28 months, while the average 
      survival-time in patients with lower levels of sVEGF (<100 pg/ml) was 35 months, 
      indicating that the elevations in sVEGF level are correlated with patient 
      survival and tumor metastasis in ovarian carcinoma. These data suggest that VEGF 
      may be a useful serological biomarker for clinical diagnosis and prognosis of 
      ovarian cancer, for follow-up of ovarian tumor metastasis and for monitoring the 
      efficacy of therapy in patients with ovarian carcinomas.
FAU - Li, Li
AU  - Li L
AD  - Department of Gynecologic Oncology, Guangxi Medical University Cancer Institute 
      and Hospital, Nanning 530021, China. lili_temp@hotmail.com
FAU - Wang, Limei
AU  - Wang L
FAU - Zhang, Wei
AU  - Zhang W
FAU - Tang, Bujian
AU  - Tang B
FAU - Zhang, Jieqing
AU  - Zhang J
FAU - Song, Honglin
AU  - Song H
FAU - Yao, Desheng
AU  - Yao D
FAU - Tang, Yong
AU  - Tang Y
FAU - Chen, Xinqiu
AU  - Chen X
FAU - Yang, Zhihua
AU  - Yang Z
FAU - Wang, Gangduo
AU  - Wang G
FAU - Li, Xiping
AU  - Li X
FAU - Zhao, Jinshun
AU  - Zhao J
FAU - Ding, Hong
AU  - Ding H
FAU - Reed, Eddie
AU  - Reed E
FAU - Li, Qingdi Q
AU  - Li QQ
LA  - eng
GR  - P20 RR016440/RR/NCRR NIH HHS/United States
GR  - P20RR16440-010003/RR/NCRR NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (VEGFA protein, human)
RN  - 0 (Vascular Endothelial Growth Factor A)
SB  - IM
MH  - Adult
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Middle Aged
MH  - Neoplasm Metastasis
MH  - Neoplasm Staging
MH  - Ovarian Neoplasms/*blood/*pathology/surgery
MH  - Survival Rate
MH  - Treatment Outcome
MH  - Vascular Endothelial Growth Factor A/*blood
EDAT- 2004/07/28 05:00
MHDA- 2004/09/10 05:00
CRDT- 2004/07/28 05:00
PHST- 2004/07/28 05:00 [pubmed]
PHST- 2004/09/10 05:00 [medline]
PHST- 2004/07/28 05:00 [entrez]
PST - ppublish
SO  - Anticancer Res. 2004 May-Jun;24(3b):1973-9.